Roche Said to Return Diabetes Drug Rights to Ipsen
This article is for subscribers only.
Roche Holding AG returned rights to the experimental diabetes drug taspoglutide to developer Ipsen SA after patients dropped out of trials because of side effects, according to two people with knowledge of the matter.
Roche told Ipsen of the decision this week, and plans to announce it tomorrow with 2010 earnings, according to one of the people, who declined to be identified because the information is confidential. Claudia Schmitt, a spokeswoman for Roche in Basel, Switzerland, and Didier Veron, an Ipsen spokesman in Boulogne-Billancourt, France, declined to comment.